The University of Southampton
University of Southampton Institutional Repository

CHCHD10 variants in amyotrophic lateral sclerosis: where is the evidence?

CHCHD10 variants in amyotrophic lateral sclerosis: where is the evidence?
CHCHD10 variants in amyotrophic lateral sclerosis: where is the evidence?

Objective: After the initial report of a CHCHD10 mutation in mitochondrial disease with features resembling amyotrophic lateral sclerosis (ALS), CHCHD10 mutations have been considered to be a frequent cause for ALS. However, the exact pathogenicity and clinical significance of these mutations remain unclear. Here, we aimed to determine the role of CHCHD10 mutations in ALS. Methods: We analyzed 4,365 whole genome sequenced ALS patients and 1,832 controls from 7 different countries and examined all nonsynonymous single nucleotide variants in CHCHD10. These were tested for association with ALS, independently and in aggregate using several genetic burden tests (including sequence kernel association test [SKAT], optimal unified test [SKAT-O], and Firth logistic regression). Results: We identified 3 new variants in cases, but only 1 was ALS-specific. Also, 1 control-specific mutation was identified. There was no increased burden of rare coding mutations among ALS patients compared to controls (p = 0.86, p = 0.86, and p = 0.88 for SKAT, SKAT-O, and Firth, respectively). The few carriers with potential pathogenic CHCHD10 mutations exhibited a slowly progressive ALS-like phenotype with atypical features such as myopathy and deafness. Interpretation: CHCHD10 mutations seem to be a far less prevalent cause of pure ALS than previously suggested, and instead appear related to more complex phenotypes. There appears to be insufficient evidence for the pathogenicity of most previously reported variants in pure ALS. This study shows that routine testing for CHCHD10 mutations in pure ALS is not recommended and illustrates the importance of sufficient genetic and functional evidence in establishing pathogenicity of genetic variants. Ann Neurol 2018;83:110–116.

0364-5134
110-116
Tazelaar, Gijs H.P.
e52f61b9-9b3b-49fb-880d-81bdbabe067a
van Rheenen, Wouter
13e9972c-a115-475f-8ffe-3753e93254fe
Pulit, Sara L.
2acf01b1-deb6-40fe-bd87-2b7028939067
van der Spek, Rick A.A.
e5ce8ba5-3071-4055-81a2-da25816e580a
Dekker, Annelot M.
6bbadf33-9710-4c31-bf5b-8e3d71ba3141
Moisse, Matthieu
c3d9959b-5964-4823-a40d-153c2fecceb8
McLaughlin, Russell L.
b1cfa275-192e-48a5-bc26-26ef74828cf9
Sproviero, William
f0231df6-ec34-456b-976d-d66ec3f3228f
Kenna, Kevin P.
abfe9493-e80b-447e-99bc-8d3af49e9300
Kooyman, Maarten
ccdb8c75-8681-4809-99a9-8fc715b9474b
van Doormaal, Perry T.C.
ab028f94-e70e-478b-a550-a236289c1d47
van Eijk, Kristel E.
05f0e4ba-3e88-43f8-a816-2de836d25b90
Middelkoop, Bas M.
ab48e5a2-1411-4a87-b331-5f9d9027481b
Schellevis, Raymond D.
e2d89708-e7ca-405c-ada2-e2270607eb41
Brands, William J.
d932d9ce-b26d-46df-b0be-5bfa2c03eb15
Al-Chalabi, Ammar
8ac40bc3-a3c0-47ad-afa7-37e08f7aab6f
Morrison, Karen E.
f00890f0-2fde-4dbd-a73b-7422e1b0ede8
Shaw, Pamela J.
3d0a5c6f-9610-45be-a0bc-5b6888003028
Shaw, Christopher E.
ad432fe6-4928-445b-a3e1-aaba83c6a530
Newhouse, Stephen E.
62b212ba-65ed-43ec-a6e5-62cf9e677016
van Es, Michael A.
dffcd987-c214-4d52-a97a-8012e21cfa7a
Basak, A. Nazli
e4b777d8-00d2-45c9-93f5-02d0f36e2278
Akçimen, Fulya
0843908a-eee6-4abe-b047-6020f56e4981
Kocoglu, Cemile
dc2b8887-40f1-42b3-887b-0e0d4a34d7f9
Tunca, Ceren
2acc4f31-03e9-43bf-9f69-c3a07f779eb6
Povedano, Monica
c0206e02-58ff-46e4-8b65-b3798cb0537a
Mora, Jesus S.
966f81d3-8478-476c-8479-2bdfc3b68095
Glass, Jonathan D.
5a0cca90-f97f-4f2f-95dc-5dc4fe8937fe
Van Damme, Philip
54a5cfff-da0a-4eb9-a0a9-15ffc8058525
Robberecht, Wim
d91a4719-00b2-4a40-99ef-04bcdff6cae5
HardimanMD, Orla
2fd8d6f7-c507-41b1-9bf6-b8f1feae914d
Landers, John E.
828d93e1-2073-4c2d-b075-9433b83dd1e2
van den Berg, Leonard H.
bd6ed390-a56e-48d3-8273-a139bdaca4da
Veldink, Jan H.
7c073868-8350-4d7a-b345-86541b34e3a2
Project MinE ALS Sequencing Consortium
Tazelaar, Gijs H.P.
e52f61b9-9b3b-49fb-880d-81bdbabe067a
van Rheenen, Wouter
13e9972c-a115-475f-8ffe-3753e93254fe
Pulit, Sara L.
2acf01b1-deb6-40fe-bd87-2b7028939067
van der Spek, Rick A.A.
e5ce8ba5-3071-4055-81a2-da25816e580a
Dekker, Annelot M.
6bbadf33-9710-4c31-bf5b-8e3d71ba3141
Moisse, Matthieu
c3d9959b-5964-4823-a40d-153c2fecceb8
McLaughlin, Russell L.
b1cfa275-192e-48a5-bc26-26ef74828cf9
Sproviero, William
f0231df6-ec34-456b-976d-d66ec3f3228f
Kenna, Kevin P.
abfe9493-e80b-447e-99bc-8d3af49e9300
Kooyman, Maarten
ccdb8c75-8681-4809-99a9-8fc715b9474b
van Doormaal, Perry T.C.
ab028f94-e70e-478b-a550-a236289c1d47
van Eijk, Kristel E.
05f0e4ba-3e88-43f8-a816-2de836d25b90
Middelkoop, Bas M.
ab48e5a2-1411-4a87-b331-5f9d9027481b
Schellevis, Raymond D.
e2d89708-e7ca-405c-ada2-e2270607eb41
Brands, William J.
d932d9ce-b26d-46df-b0be-5bfa2c03eb15
Al-Chalabi, Ammar
8ac40bc3-a3c0-47ad-afa7-37e08f7aab6f
Morrison, Karen E.
f00890f0-2fde-4dbd-a73b-7422e1b0ede8
Shaw, Pamela J.
3d0a5c6f-9610-45be-a0bc-5b6888003028
Shaw, Christopher E.
ad432fe6-4928-445b-a3e1-aaba83c6a530
Newhouse, Stephen E.
62b212ba-65ed-43ec-a6e5-62cf9e677016
van Es, Michael A.
dffcd987-c214-4d52-a97a-8012e21cfa7a
Basak, A. Nazli
e4b777d8-00d2-45c9-93f5-02d0f36e2278
Akçimen, Fulya
0843908a-eee6-4abe-b047-6020f56e4981
Kocoglu, Cemile
dc2b8887-40f1-42b3-887b-0e0d4a34d7f9
Tunca, Ceren
2acc4f31-03e9-43bf-9f69-c3a07f779eb6
Povedano, Monica
c0206e02-58ff-46e4-8b65-b3798cb0537a
Mora, Jesus S.
966f81d3-8478-476c-8479-2bdfc3b68095
Glass, Jonathan D.
5a0cca90-f97f-4f2f-95dc-5dc4fe8937fe
Van Damme, Philip
54a5cfff-da0a-4eb9-a0a9-15ffc8058525
Robberecht, Wim
d91a4719-00b2-4a40-99ef-04bcdff6cae5
HardimanMD, Orla
2fd8d6f7-c507-41b1-9bf6-b8f1feae914d
Landers, John E.
828d93e1-2073-4c2d-b075-9433b83dd1e2
van den Berg, Leonard H.
bd6ed390-a56e-48d3-8273-a139bdaca4da
Veldink, Jan H.
7c073868-8350-4d7a-b345-86541b34e3a2

Project MinE ALS Sequencing Consortium (2018) CHCHD10 variants in amyotrophic lateral sclerosis: where is the evidence? Annals of Neurology, 84 (1), 110-116. (doi:10.1002/ana.25273).

Record type: Article

Abstract

Objective: After the initial report of a CHCHD10 mutation in mitochondrial disease with features resembling amyotrophic lateral sclerosis (ALS), CHCHD10 mutations have been considered to be a frequent cause for ALS. However, the exact pathogenicity and clinical significance of these mutations remain unclear. Here, we aimed to determine the role of CHCHD10 mutations in ALS. Methods: We analyzed 4,365 whole genome sequenced ALS patients and 1,832 controls from 7 different countries and examined all nonsynonymous single nucleotide variants in CHCHD10. These were tested for association with ALS, independently and in aggregate using several genetic burden tests (including sequence kernel association test [SKAT], optimal unified test [SKAT-O], and Firth logistic regression). Results: We identified 3 new variants in cases, but only 1 was ALS-specific. Also, 1 control-specific mutation was identified. There was no increased burden of rare coding mutations among ALS patients compared to controls (p = 0.86, p = 0.86, and p = 0.88 for SKAT, SKAT-O, and Firth, respectively). The few carriers with potential pathogenic CHCHD10 mutations exhibited a slowly progressive ALS-like phenotype with atypical features such as myopathy and deafness. Interpretation: CHCHD10 mutations seem to be a far less prevalent cause of pure ALS than previously suggested, and instead appear related to more complex phenotypes. There appears to be insufficient evidence for the pathogenicity of most previously reported variants in pure ALS. This study shows that routine testing for CHCHD10 mutations in pure ALS is not recommended and illustrates the importance of sufficient genetic and functional evidence in establishing pathogenicity of genetic variants. Ann Neurol 2018;83:110–116.

Text
CHCHD10_Manuscript_Annals_Final_20180504 - Accepted Manuscript
Download (146kB)
Text
CHCHD10_Supplementary_Annals_Final_20180504 - Accepted Manuscript
Download (26kB)

More information

Accepted/In Press date: 4 June 2018
e-pub ahead of print date: 16 July 2018
Published date: July 2018

Identifiers

Local EPrints ID: 425106
URI: http://eprints.soton.ac.uk/id/eprint/425106
ISSN: 0364-5134
PURE UUID: 08a06350-25d9-467a-8e2f-e05124185c46
ORCID for Karen E. Morrison: ORCID iD orcid.org/0000-0003-0216-5717

Catalogue record

Date deposited: 10 Oct 2018 16:30
Last modified: 18 Mar 2024 05:20

Export record

Altmetrics

Contributors

Author: Gijs H.P. Tazelaar
Author: Wouter van Rheenen
Author: Sara L. Pulit
Author: Rick A.A. van der Spek
Author: Annelot M. Dekker
Author: Matthieu Moisse
Author: Russell L. McLaughlin
Author: William Sproviero
Author: Kevin P. Kenna
Author: Maarten Kooyman
Author: Perry T.C. van Doormaal
Author: Kristel E. van Eijk
Author: Bas M. Middelkoop
Author: Raymond D. Schellevis
Author: William J. Brands
Author: Ammar Al-Chalabi
Author: Karen E. Morrison ORCID iD
Author: Pamela J. Shaw
Author: Christopher E. Shaw
Author: Stephen E. Newhouse
Author: Michael A. van Es
Author: A. Nazli Basak
Author: Fulya Akçimen
Author: Cemile Kocoglu
Author: Ceren Tunca
Author: Monica Povedano
Author: Jesus S. Mora
Author: Jonathan D. Glass
Author: Philip Van Damme
Author: Wim Robberecht
Author: Orla HardimanMD
Author: John E. Landers
Author: Leonard H. van den Berg
Author: Jan H. Veldink
Corporate Author: Project MinE ALS Sequencing Consortium

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×